AngioDynamics spin-off nears completion

Article

E-Z-EM announced Aug. 19 a common stock dividend of 9.2 million shares for its subsidiary AngioDynamics. The dividend, payable on Oct. 30 to E-Z-EM shareholders of record on Oct. 11, will mark AngioDynamics' debut as a separate company. The announcement

E-Z-EM announced Aug. 19 a common stock dividend of 9.2 million shares for its subsidiary AngioDynamics. The dividend, payable on Oct. 30 to E-Z-EM shareholders of record on Oct. 11, will mark AngioDynamics' debut as a separate company. The announcement came after E-Z-EM received a ruling from the IRS confirming that the dividend would be free from federal income taxes to E-Z-EM and its stockholders, except for any cash received by stockholders instead of a fractional share. AngioDynamics designs, develops, manufactures, and markets medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.